Insider · CIK 0001827621
Milton H. Werner
ceopresidentofficerdirector
Files at IKT (Inhibikase Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,643 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,643 | $0.00 | $0 | 3,643 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,667 | $0.00 | $0 | 16,667 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,834 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,834 | $0.00 | $0 | 20,834 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jan 22, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,315,056 | $0.00 | $0 | 5,315,056 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,207,671 | $0.00 | $0 | 2,207,671 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,059,744 | $0.00 | $0 | 4,059,744 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.